The new consortium CARE (Corona Accelerated R&D in Europe), supported by the Innovative Medicines Initiative (IMI) public-private partnership, announced its launch today to accelerate the discovery and development of...
Bacteria show a wide range of capabilities in withstanding antibiotic treatment or attack by our immune system, which are great challenges in infection research. Scientists at the Würzburg-based Helmholtz Institute for...
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction – rather, the immune response is caught in a continuous loop of activation and...
Who has overcome an infection with the virus without noticing, and how many people have already produced protective antibodies against the new coronavirus? Various antibody studies are now under way that will provide...
The intestinal microbiota plays a central role for human physiology. Traditional studies have focused on the changes in microbiota composition under diverse conditions. Recently, efforts shifted towards understanding...
With the aim of obtaining a better overview of the occurrence of SARS-CoV-2 infections, a nationwide antibody study conducted by the Helmholtz Centre for Infection Research (HZI) was launched in the district of...
Jun Prof Jesko Köhnke heads the junior research group “Structural Biology of Biosynthetic Enzymes” at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a site of the Helmholtz Centre for Infection...
The Leibniz Institute for New Materials (INM), Saarland University (UdS) and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) are launching the Leibniz Science Campus “Living Therapeutic Materials” on...
Prof Anna K. H. Hirsch recently received a prestigious European grant with a total funding volume of 3.2 million euros to initiate an Innovative Training Network (ITN) in the framework of the Marie Skłodowska-Curie...
